Literature DB >> 20044011

Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile.

Ellie J C Goldstein1, Diane M Citron, Kerin L Tyrrell, Yumi A Warren.   

Abstract

We compared the time-kill activities of telavancin, vancomycin and metronidazole at concentrations of 2 times, 4 times, and 8 times their respective MICs against five Clostridium difficile strains including REA type BI, using inocula that contained predominantly either vegetative cells or spores. Telavancin MICs (0.125-0.25 microg/ml) were 2-8-fold lower than those of vancomycin. Telavancin was bacteriostatic, reducing the inoculum by 1-2.5 log(10) after 24 h. No major differences occurred with the different inoculum forms or the REA types. Although telavancin MICs were 2-8 times lower than vancomycin, both demonstrated similar bacteriostatic activity against C. difficile while metronidazole was bactericidal. 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20044011     DOI: 10.1016/j.anaerobe.2009.12.002

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  4 in total

Review 1.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

2.  Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole.

Authors:  Patrick M Chong; Tarah Lynch; Stuart McCorrister; Pamela Kibsey; Mark Miller; Denise Gravel; Garrett R Westmacott; Michael R Mulvey
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

3.  Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin.

Authors:  Sandra Maaß; Andreas Otto; Dirk Albrecht; Katharina Riedel; Anke Trautwein-Schult; Dörte Becher
Journal:  Cells       Date:  2018-11-15       Impact factor: 6.600

4.  Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay.

Authors:  Angie M Jarrad; Mark A T Blaskovich; Anggia Prasetyoputri; Tomislav Karoli; Karl A Hansford; Matthew A Cooper
Journal:  Front Microbiol       Date:  2018-07-02       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.